These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 32988985)
1. Fibrodysplasia ossificans progressiva: current concepts from bench to bedside. Kaliya-Perumal AK; Carney TJ; Ingham PW Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32988985 [TBL] [Abstract][Full Text] [Related]
2. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1 Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986 [TBL] [Abstract][Full Text] [Related]
3. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737 [TBL] [Abstract][Full Text] [Related]
4. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation. Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819 [TBL] [Abstract][Full Text] [Related]
5. Spatial patterns of heterotopic ossification in fibrodysplasia ossificans progressiva correlate with anatomic temperature gradients. Wang H; De Cunto CL; Pignolo RJ; Kaplan FS Bone; 2021 Aug; 149():115978. PubMed ID: 33915334 [TBL] [Abstract][Full Text] [Related]
6. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907 [TBL] [Abstract][Full Text] [Related]
7. Fibrodysplasia ossificans progressiva. Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989 [TBL] [Abstract][Full Text] [Related]
8. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP). Towler OW; Shore EM Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058 [TBL] [Abstract][Full Text] [Related]
9. The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva. Ye Z; Wang S; Shan C; Zhu Q; Xue Y; Zhang K Orphanet J Rare Dis; 2023 May; 18(1):111. PubMed ID: 37165433 [TBL] [Abstract][Full Text] [Related]
10. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva. Srinivasan D; Arostegui M; Goebel EJ; Hart KN; Aykul S; Lees-Shepard JB; Idone V; Hatsell SJ; Economides AN Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254701 [TBL] [Abstract][Full Text] [Related]